CSNP Peptides Bind Spike Protein RBD to Block ACE2 Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective solutions to prevent or treat SARS-CoV-2 infection by blocking the interaction between the virus's spike protein and the ACE2 receptor, which is crucial for cell entry and immune evasion.
Innovation Solution
Development of pharmaceutical, co-administration, and health functional food compositions containing CSNP1, CSNP2, CSNP3, or CSNP4 peptides that bind to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, inhibiting its interaction with the ACE2 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies or antibody-related molecules are developed to bind to RBD and inhibit spike protein-ACE2 interaction, then prevention and treatment of SARS-CoV-2 infection can be achieved, but the complexity of identifying effective binders and the time required for development increase
Solution Approach 1:
The patent uses computational modeling to create virtual copies of antibody binders (CSNPs) based on known effective antibody structures. Instead of testing countless real antibodies, the system generates and evaluates computational models that replicate the binding mechanisms of proven antibodies, significantly reducing development time and complexity while maintaining effectiveness.
Solution Approach 2:
The patent replaces physical experimentation with computational simulations. Molecular dynamics simulations and free energy calculations substitute for traditional wet-lab screening methods, allowing rapid evaluation of thousands of potential binders in silico before selecting candidates for experimental validation, thereby reducing both time and resource requirements.
2Loss of time
If computational methods are used to identify effective binders, then development time is reduced, but the precision and accuracy of predicting binding effectiveness may be compromised
Solution Approach 1:
The patent introduces free energy calculations as an intermediary step between structural modeling and experimental validation. This computational metric serves as a bridge that predicts binding effectiveness with high accuracy, allowing the selection of only the most promising candidates for experimental testing, thus maintaining precision while reducing overall development time.
Solution Approach 2:
The patent employs molecular dynamics simulations to replace preliminary experimental screening. These simulations accurately model the dynamic behavior of protein complexes and provide reliable predictions of binding stability and affinity, maintaining measurement precision while dramatically reducing the time required to evaluate potential binders.
3Measurement precision
If multiple computational simulations are performed to ensure binder stability and effectiveness, then prediction accuracy improves, but computational resources and time required increase
Solution Approach 1:
The patent performs preliminary computational filtering using less computationally intensive methods to identify and eliminate clearly ineffective candidates before applying more resource-intensive molecular dynamics simulations and free energy calculations. This staged approach ensures high prediction accuracy for the final selected binders while minimizing overall computational resource consumption.
Solution Approach 2:
The patent applies comprehensive computational analysis only to a small subset of pre-selected candidate binders that have already passed initial screening filters. By performing extensive simulations on only the most promising candidates rather than all possible binders, the system achieves high prediction accuracy for the final selection while keeping total computational resource usage manageable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CSNP peptides effectively interfere with the viral entry mechanism, providing a composition for preventing or treating SARS-CoV-2 infection by stabilizing their structure and maintaining binding affinity, thus offering a potential therapeutic agent.
Implementation Method 1
CSNP1, CSNP2, CSNP3, or CSNP4 binds to a receptor binding domain (RBD) of a spike protein of SARSCoV-2 and inhibits interaction of the spike protein of SARS-CoV-2 with ACE2
Data Source
AI summary
The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).